Seeing Is Believing
Currently out of the existing stock ratings of Evan Seigerman, 121 are a BUY (56.28%), 78 are a HOLD (36.28%), 16 are a SELL (7.44%).
Analyst Evan Seigerman, currently employed at BMO, carries an average stock price target met ratio of 63.97% that have a potential upside of 20.5% achieved within 154 days.
Evan Seigerman’s has documented 434 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NBIX, Neurocrine Biosciences at 06-May-2025.
Analyst best performing recommendations are on STSA (SATSUMA PHARMACEUTICALS).
The best stock recommendation documented was for ACRX (ACELRX PHARMACEUTICALS) at 3/24/2020. The price target of $20 was fulfilled within 1 day with a profit of $1 (5.26%) receiving and performance score of 52.63.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
1 years 8 months 6 days ago
(25-Sep-2023)
0/3 (0%)
$95.4 (213.90%)
Buy
$160
3 years 5 months 30 days ago
(01-Dec-2021)
0/1 (0%)
$74.6 (87.35%)
Sell
$16.6
$15.47 (1369.03%)
$16.8
4 years 6 months 25 days ago
(06-Nov-2020)
5/5 (100%)
$-12.4 (-42.76%)
268
Buy
$120
$118.87 (10519.47%)
6 years 22 days ago
(09-May-2019)
0/1 (0%)
$56.4 (88.68%)
Buy
$200
$198.87 (17599.12%)
$140
6 years 6 months 29 days ago
(02-Nov-2018)
0/2 (0%)
$104 (108.33%)
Which stock is Evan Seigerman is most bullish on?
Which stock is Evan Seigerman is most reserved on?
What Year was the first public recommendation made by Evan Seigerman?